In this video, Aruna Padmanabhan, MD, discusses the management of side effects seen in patients receiving PI3K inhibitors for ...

New research indicates that a drug called Inavolisib is effective at treating a type of metastatic breast cancer with a ...

In this video, Aruna Padmanabhan, MD, discusses the evaluation of PI3K inhibitor combinations as first-line treatment for patients with metastatic breast cancer.

In a nutshell Researchers discovered how a specific genetic mutation (PIK3CA) changes the way blood vessel cancers grow and evade the immune system in both dogs and humans, potentially leading to new ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Updated overall survival (OS) results – a key secondary endpoint – reinforce the significant benefit of the Itovebi TM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

Challenges in patient selection for surgical options in V600E BRAF–mutated metastatic colorectal cancer.

Ignite Proteomics offers the only commercially available and clinically validated assay that measures both the expression and ...

Red bars indicate co-occurring mutations. EGFR_ECD, extracellular domain mutations of EGFR; EGFR_KD, kinase domain mutations of EGFR; PIK3CA_KD, kinase domain mutation of PIK3CA; PIK3CA_HD ...